Algeta - Notice of Annual General Meeting 2013

Marketwired

OSLO, NORWAY--(Marketwire - Mar 19, 2013) - Algeta ASA (OSE: ALGETA), a company focused onthedevelopment of novel targeted cancer therapeutics, announces its AnnualGeneralMeeting 2013:

Algeta's Annual General Meeting will be held on 11 April 2013 at 16:00hours(CET) at the offices of Algeta ASA at Kjelsåsveien 172A, Oslo, Norway.

Please find attached the Notice of Algeta ASA's Annual General Meeting,proposedamended charter for the nomination committee, and attendance slip and proxyform. These are, together with the annual report, also available onwww.algeta.com in the Investor section.

###

About Algeta

Algeta is a company focused on developing novel targeted therapies forpatientswith cancer based on its alpha-pharmaceutical platform. The Company isheadquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC,based inCambridge, MA performing commercial marketing operations in the US. Algetaislisted on the Oslo Stock Exchange (ALGETA.OL). For more informationpleasevisit www.algeta.com.

Notice of Attendance of Annual General Meeting in Algeta ASA:http://hugin.info/134655/R/1686069/552595.pdf

Attendance and proxy form:http://hugin.info/134655/R/1686069/552597.pdf

Proposed amended charter for the Nomination Committee:http://hugin.info/134655/R/1686069/552596.pdf

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Algeta ASA via Thomson Reuters ONE[HUG#1686069]

Contact:

For further information, please contact:

Mike Booth / Renate Birkeli
Communications & Corporate Affairs
+47 23 00 67 32
Email Contact

Media enquiries:

Mark Swallow
Citigate Dewe Rogerson
+44 207 638 9571
Email Contact

Knut Ekern
Gambit Hill & Knowlton
+47 22 04 82 00
Email Contact

Kari Watson
MacDougall Biomedical Communications
+1 781 235 3060
Email Contact

US investor enquiries:

Tricia Swanson
The Trout Group
+1 646 378 2953
Email Contact

View Comments (0)